Teva Pharmaceuticals has agreed to pay $35 million to resolve a federal antitrust class action alleging the company engaged in anticompetitive conduct to block generic competition for its QVAR line of inhaled corticosteroid products [1]. The settlement was announced May 6, 2026, and would end litigation brought on behalf of purchasers who alleged they paid artificially inflated prices as a result of Teva's alleged market-exclusivity tactics [1].
The claims center on conduct that plaintiffs contend violated federal antitrust law, including provisions of the Sherman Act, which prohibits agreements and unilateral conduct that unreasonably restrain trade or monopolize markets. QVAR, a beclomethasone dipropionate inhaler used to treat asthma, has been a significant revenue product for Teva. The class action alleged that Teva's actions, the specific mechanisms of which include conduct aimed at delaying or deterring generic entry, harmed downstream purchasers by sustaining above-competitive prices for the product [1]. Pay-for-delay arrangements and product-hopping strategies have been recurring enforcement targets in pharmaceutical antitrust litigation, though the precise theory of liability in this matter was not detailed in available sources.
The settlement resolves the class action at the federal level and averts what would have been a complex and resource-intensive trial [1]. Class action antitrust settlements of this magnitude typically require judicial approval, including findings that the agreement is fair, reasonable, and adequate for the proposed settlement class. The procedural posture, including whether a preliminary approval motion has been filed or a fairness hearing scheduled, was not confirmed in available sources. Class members who qualify as direct or indirect purchasers would generally be entitled to submit claims for a share of the net settlement fund following court approval and claims administration.
The resolution adds to a pattern of significant pharmaceutical antitrust settlements in recent years, as plaintiffs' firms and state attorneys general have pursued manufacturers accused of suppressing generic competition across a range of branded drug markets. For Teva specifically, the company has faced multiple antitrust and regulatory actions in the United States involving its generic and branded drug portfolios. A $35 million settlement, while notable, falls within the range of outcomes seen in mid-tier pharmaceutical antitrust class actions, where damages often turn on the duration of alleged exclusionary conduct and the volume of affected commerce. Court approval and a final claims process will determine the timeline for any distribution to class members [1].